SOPHiA GENETICS (NASDAQ:SOPH) President Ross Muken Sells 4,442 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) President Ross Muken sold 4,442 shares of the business’s stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $4.76, for a total value of $21,143.92. Following the sale, the president owned 685,232 shares in the company, valued at approximately $3,261,704.32. The trade was a 0.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ross Muken also recently made the following trade(s):

• On Friday, April 10th, Ross Muken sold 3,687 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.69, for a total value of $17,292.03.
• On Thursday, April 9th, Ross Muken sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total value of $9,243.00.
• On Wednesday, April 8th, Ross Muken sold 2,786 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total value of $13,484.24.
• On Tuesday, April 7th, Ross Muken sold 2,424 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total value of $11,804.88.
• On Thursday, March 19th, Ross Muken sold 1,183 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total value of $5,666.57.

SOPHiA GENETICS Stock Up 2.3%

SOPHiA GENETICS stock opened at $4.96 on Wednesday. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.84 and a current ratio of 1.96. The business’s 50-day simple moving average is $4.74 and its two-hundred day simple moving average is $4.72. The company has a market cap of $339.71 million, a PE ratio of -9.73 and a beta of 1.04. SOPHiA GENETICS SA has a fifty-two week low of $2.58 and a fifty-two week high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.08). The company had revenue of $21.71 million during the quarter, compared to analyst estimates of $21.20 million. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. Equities analysts anticipate that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on SOPH. BTIG Research reissued a “buy” rating and set a $7.00 target price on shares of SOPHiA GENETICS in a report on Tuesday, March 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Finally, Guggenheim increased their target price on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a report on Monday, January 26th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $7.00.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of large investors have recently made changes to their positions in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after purchasing an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC grew its position in SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after acquiring an additional 1,481,636 shares during the period. Alta Wealth Advisors LLC purchased a new position in SOPHiA GENETICS in the third quarter worth approximately $6,708,000. Royce & Associates LP purchased a new position in SOPHiA GENETICS in the fourth quarter worth approximately $2,009,000. Finally, 1492 Capital Management LLC purchased a new position in SOPHiA GENETICS in the fourth quarter worth approximately $973,000. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Neutral Sentiment: Aggregate insider activity: company executives and other insiders sold a combined ~43,400 shares across transactions on April 10 and April 13. Sales were executed under pre-arranged Rule 10b5-1 plans and were reported in SEC Form 4 filings. SEC Form 4
• Neutral Sentiment: CEO Jurgi Camblong sold 12,232 shares on April 10 and 4,399 shares on April 13 (total ~16,631 shares). Trades were made under a 10b5-1 plan to cover tax withholding tied to equity vesting; his remaining direct stake remains large (>3.7M shares). SEC Form 4
• Neutral Sentiment: President Ross Muken sold 3,687 shares on April 10 and 4,442 shares on April 13 (~8,129 shares). Transactions were under a 10b5-1 plan and described as tax-related for vested awards. SEC Form 4
• Neutral Sentiment: Other insiders (Philippe Menu and Zhenyu Xu) each made paired sales on April 10 and April 13 totaling ~8,125 and ~8,120 shares respectively; Well Daan Van sold 2,400 shares on April 10. All trades were 10b5-1, tax-withholding sales. SEC Form 4 (Menu) SEC Form 4 (Xu) SEC Form 4 (Van)

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.